Combination of valproic acid and ATRA restores RARβ2 expression and induces differentiation in cervical cancer through the PI3K/Akt pathway

Current Molecular Medicine

Volumn 12, Issue 3, 2012, Pages 342-354

  Feng, D ^a   Cao, Z ^a,b   Li, C ^a   Zhang, L ^a   Zhou, Y ^a   Ma, J ^a   Liu, R ^a   Zhou, H ^a   Zhao, W ^a   Wei, H ^c   Ling, B ^a  

^a ANHUI PROVINCIAL HOSPITAL   (China)

^b Hefei Third People's Hospital   (China)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

All trans retinoic acid; Cell cycle; Cervical cancer; Differentiation; RAR 2; Valproic acid

Indexed keywords

CISPLATIN; HISTONE H3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P21; PROTEIN P53; RETINOIC ACID; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA2; STAT3 PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE CONTROL; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; UPREGULATION; UTERINE CERVIX CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; FEMALE; HELA CELLS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, RETINOIC ACID; SIGNAL TRANSDUCTION; TRETINOIN; UTERINE CERVICAL NEOPLASMS; VALPROIC ACID;

EID: 84863124994     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652412799218949     Document Type: Article

References (47)

1. Arbyn M, Castellsague X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011; 21 (2): 2675-2686.
2. Abu J, Batuwangala M, Herbert K, Symonds P. Retinoic acid and retinoid receptors: potential chemopreventive andtherapeutic role in cervical cancer. Lancet Oncol 2005; 6: 712-720.
3. Ferenczy A, Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol 2002; 3: 11-16.
4. Duenas-Gonzalez A, Lizano M, Candelaria M, Cetina L, Arce C, Cervera E. Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer 2005; 4: 38.
5. Klopp AH, Eifel PJ. Chemoradiotherapy for cervical cancer in 2010. Curr Oncol Rep 2011; 13: 77-85.
6. Mai A, Massa S, Rotili D, et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 2005; 25: 261-309.
7. Mork CN, Faller DV, Spanjaard RA. A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors. Curr Pharm Des 2005; 11: 1091-1094.
8. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003; 4: 13-18.
9. Rosato RR, Grant S. Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2003; 2: 30-37.
10. You JS, Kang JK, Lee EK, et al. Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells. Oncogene 2008; 27: 1376-1386.
11. Lin Z, Bazzaro M, Wang MC, Chan KC, Peng S, Roden RB. Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res 2009;15:570-577.
12. Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer 2005; 4: 22.
13. Kuendgen A, Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer 2007; 110: 943-954.
14. Candelaria M, Gallardo-Rincon D, Arce C, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 2007; 18: 1529-1538.
15. Greenblatt DY, Cayo MA, Adler JT, et al. Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells. Ann Surg 2008; 247: 1036-1040.
16. Braiteh F, Soriano AO, Garcia-Manero G, et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 2008; 14: 6296-6301.
17. Heim KC, White KA, Deng D, et al. Selective repression of retinoic acid target genes by RIP140 during induced tumor cell differentiation of pluripotent human embryonal carcinoma cells. Mol Cancer 2007; 6: 57.
18. Daud AI, Dawson J, DeConti RC, et al. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res 2009; 15: 2479-2487.
19. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194-202.
20. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001; 13: 477-483.
21. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16: 695-714.
22. Xu Q, Zhang Z, Zhang P, Chen W. Antisense oligonucleotides and all-trans retinoic acid have a synergistic anti-tumor effect on oral squamous cell carcinoma. BMC Cancer 2008; 8:159.
23. Manor D, Shmidt EN, Budhu A, et al. Mammary carcinomasuppression by cellular retinoic acid binding protein-II. Cancer Res 2003; 63: 4426-4433.
24. Mongan NP, Gudas LJ. Valproic acid, in combination with alltrans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells. Mol Cancer Ther 2005; 4: 477-486.
25. Narayan G, Arias-Pulido H, Koul S, et al. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer 2003; 2: 24.
26. Sirchia SM, Ferguson AT, Sironi E, et al. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene 2000; 19: 1556-1563.
27. Cote S, Rosenauer A, Bianchini A, et al. Response to histonedeacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells. Blood 2002; 100: 2586-2596.
28. Kuncharin Y, Sangphech N, Kueanjinda P, Bhattarakosol P, Palaga T. MAML1 regulates cell viability via the NF-kappaB pathway in cervical cancer cell lines. Exp Cell Res 2011; 317: 1830-1840.
29. Feng D, Peng C, Li C, et al. Identification and characterization of cancer stem-like cells from primary carcinoma of the cervix uteri. Oncol Rep 2009; 22: 1129-1134.
30. Yang Q, Tian Y, Liu S, et al. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 2007; 67: 1716-1724.
31. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-5552.
32. Vandermeers F, Hubert P, Delvenne P, et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 2009; 15: 2818-2828.
33. Steele N, Finn P, Brown R, Plumb JA. Combined inhibition of DNA methylation and histone acetylation enhances gene reexpression and drug sensitivity in vivo. Br J Cancer 2009; 100: 758-763.
34. Lamb LE, Knudsen BS, Miranti CK. E-cadherin-mediated survival of androgen-receptor-expressing secretory prostate epithelial cells derived from a stratified in vitro differentiation model. J Cell Sci 2010; 123: 266-276.
35. Perrais M, Chen X, Perez-Moreno M, Gumbiner BM. Ecadherin homophilic ligation inhibits cell growth and epidermal growth factor receptor signaling independently of other cell interactions. Mol Biol Cell 2007; 18: 2013-2025.
36. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457-463.
37. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784.
38. Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 2005; 14: 1497-1511.
39. de la Cruz Hernandez E, Perez Cardenas E, Contreras Paredes A, et al. The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study. Virol J 2007; 4: 18.
40. Borutinskaite VV, Navakauskiene R, Magnusson KE. Retinoic acid and histone deacetylase inhibitor BML-210 inhibit proliferation of human cervical cancer HeLa cells. Ann N Y Acad Sci 2006; 1091: 346-355.
41. Sami S, Hoti N, Xu HM, Shen Z, Huang X. Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. J Biochem 2008; 144: 357-362.
42. Khan MA, Jenkins GR, Tolleson WH, Creek KE, Pirisi L. Retinoic acid inhibition of human papillomavirus type 16- mediated transformation of human keratinocytes. Cancer Res 1993; 53: 905-909.
43. Meyskens FL, Jr., Surwit E, Moon TE, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst 1994; 86: 539-543.
44. Tinkle CL, Lechler T, Pasolli HA, Fuchs E. Conditional targeting of E-cadherin in skin: insights into hyperproliferative and degenerative responses. Proc Natl Acad Sci USA 2004; 101: 552-557.
45. Calautti E, Li J, Saoncella S, Brissette JL, Goetinck PF. Phosphoinositide 3-kinase signaling to Akt promotes keratinocyte differentiation versus death. J Biol Chem 2005; 280: 32856-32865.
46. Heliez C, Baricault L, Barboule N, Valette A. Paclitaxel increases p21 synthesis and accumulation of its AKTphosphorylated form in the cytoplasm of cancer cells. Oncogene 2003; 22: 3260-3268.
47. Tu CL, Chang W, Xie Z, Bikle DD. Inactivation of the calcium sensing receptor inhibits E-cadherin-mediated cell-cell adhesion and calcium-induced differentiation in human epidermal keratinocytes. J Biol Chem 2008; 283: 3519-3528.